-
Mashup Score: 18Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma - PubMed - 2 day(s) ago
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talq …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 35
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Landgren on MRD as an End Point for Multiple Myeloma Trials - 3 day(s) ago
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Despite great treatment advances in multiple myeloma, relapses are frequent and the disease remains a considerable source of morbidity and mortality.1 As treatments advance and remission is prolonged, the definition of a cure becomes increasingly relevant. In patients with chronic myeloid leukaemia, the concept of a functional cure was described as patients who had no evidence of disease but remained on therapy indefinitely;2 however, a similar unified definition does not exist for patients with multiple myeloma.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
PURPOSE The study of rare diseases, such as multiple myeloma (MM), often experiences unique research hurdles that can delay or prevent lifesaving discoveries. HealthTree Cure Hub is a first-in-class software program designed to overcome these potential research hurdles. METHODS We assessed whether HealthTree Cure Hub improved four commonly experienced research hurdles such as (1) small numbers of patient accrual to clinical trials and research studies, (2) shallow and isolated data sets, (3) high costs to answer research questions, and (4) lack of long-term follow-up patient data. RESULTS As of June 2021, HealthTree Cure Hub, with its unique portal features, has attracted 9,225 patients with MM and diverse demographic backgrounds. While completing an online health profile, patients shared comprehensive data, as well as provided consent to contribute data from electronic medical records. Portal use answered research questions using patient-driven real-world data. This also cultivated re
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO https://t.co/WOwLb9Eozv @myelomacrowd #mmsm https://t.co/bvNGdh5F4O
-
-
Mashup Score: 0
Are we ever “done” with myeloma? Jenny Ahlstrom shares her thoughts about heading back into myeloma treatment.
Source: healthtree.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3The Mayo Clinic’s PragMMatic Study Is Now Accruing Newly Diagnosed Multiple Myeloma Patients - 3 day(s) ago
Mayo Clinic’s PragMMatic Study Accruing Newly Diagnosed Multiple Myeloma Patients A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members Drs. S. Vincent Rajkumar and Shaji Kumar, the study is for the first time comparing the efficacy and side effect profiles of the three most common treatment regimens for NDMM patients. These regimens include the following:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Landgren on MRD as an End Point for Multiple Myeloma Trials - 3 day(s) ago
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Landgren on MRD as an End Point for Multiple Myeloma Trials - 3 day(s) ago
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
Fascinating! Relapsed #MMsm ➡️ CAR-T ➡️ PD ➡️ talq. Skin toxicities occurred, then resolved. In CR. Persistent ICAHT, so stem cell boost given ➡️ skin toxicities recurred forcefully 😳 Newly made T cells more redirectable & less exhausted with bsAbs? https://t.co/I0QgpXXpQt https://t.co/MybJnxprmT